• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC IRELAND RESOLUTE ONYX RX; STENT, CORONARY, DRUG-ELUTING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC IRELAND RESOLUTE ONYX RX; STENT, CORONARY, DRUG-ELUTING Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Stroke/CVA (1770); Myocardial Infarction (1969); Occlusion (1984); Thrombus (2101); Stenosis (2263); Injury (2348)
Event Date 01/28/2019
Event Type  Injury  
Manufacturer Narrative
Journal article: long-term clinical outcomes of isolated ostial left anterior descending disease treatment: ostial stenting versus left main cross-over stenting authors: gianluca rigatelli, marco zuin, enrico baracca, et.Al.Journal: cardiovascular revascularization medicine year: 2019 reference: https://doi.Org/10.1016/j.Carrev.2019.01.030.There is no established or suspected causal relationship between the device and the death events.Deaths are common occurrences in clinical studies, however the cause(s) of death are often not characterized or clearly associated with a particular product.Therefore, deaths will not be considered reportable unless clearly stated as being associated with a medtronic device.Date of publication procedural images were provided in the article however they do not refer to a resolute onyx stent device and so do not confirm any of the adverse events reported for the resolute onyx device.If information is provided in the future, a supplemental report will be issued.
 
Event Description
A journal article was submitted.The aim of the study was to compare the long term clinical outcomes of two stenting techniques, ostial stenting versus left main cross-over stenting, used in the treatment of isolated ostial left anterior descending disease.Resolute integrity and resolute onyx rx coronary drug eluting stents were among those implanted in the patients.Clinical outcomes reported in the study population included cardiac death, myocardial infarction, stroke, tvr (target vessel revascularisation), in-stent restenosis, stent thrombosis and abrupt vessel occlusion.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
RESOLUTE ONYX RX
Type of Device
STENT, CORONARY, DRUG-ELUTING
Manufacturer (Section D)
MEDTRONIC IRELAND
parkmore business park west
galway
IE 
Manufacturer (Section G)
MEDTRONIC IRELAND
parkmore business park west
galway
IE  
Manufacturer Contact
toni o'doherty
parkmore business park west
galway 
IE  
091708734
MDR Report Key9675356
MDR Text Key178005658
Report Number9612164-2020-00584
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)N
Reporter Country CodeIT
PMA/PMN Number
P160043
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,literature
Reporter Occupation Other
Type of Report Initial
Report Date 02/06/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 01/15/2020
Initial Date FDA Received02/06/2020
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age73 YR
-
-